Suppr超能文献

鉴定细胞间黏附分子 1(ICAM-1)为糖基化障碍细胞中的低聚糖标记物。

Identification of intercellular cell adhesion molecule 1 (ICAM-1) as a hypoglycosylation marker in congenital disorders of glycosylation cells.

机构信息

Genetic Disease Program, Sanford Children's Health Research Center, Sanford-Burnham Medical Research Institute, La Jolla, California 92037, USA.

出版信息

J Biol Chem. 2012 May 25;287(22):18210-7. doi: 10.1074/jbc.M112.355677. Epub 2012 Apr 11.

Abstract

Many human inherited disorders cause protein N-glycosylation defects, but there are few cellular markers to test gene complementation for such defects. Plasma membrane glycoproteins are potential biomarkers because they may be reduced or even absent in plasma membranes of glycosylation-deficient cells. We combined stable isotope labeling by amino acids in cell culture (SILAC) with linear ion trap mass spectrometry (LTQ Orbitrap(TM)) to identify and quantify membrane proteins from wild-type CHO and glycosylation-deficient CHO (Lec9) cells. We identified 165 underrepresented proteins from 1447 unique quantified proteins, including 18 N-glycosylated plasma membrane proteins. Using various methods, we found that intercellular cell adhesion molecule 1 (ICAM-1) was reduced in Lec9 cells and in fibroblasts from 31 congenital disorder of glycosylation (CDG) patients compared with normal controls. Mannose supplementation of phosphomannose isomerase-deficient CDG-Ib (MPI-CDG) cells and complementation with PMM2 in PMM2-deficient CDG-Ia (PMM2-CDG) cells partially corrected hypoglycosylation based on increased ICAM-1 presence on the plasma membrane. These data indicate that ICAM-1 could be a useful hypoglycosylation biomarker to assess gene complementation of CDG-I patient cells and to monitor improved glycosylation in response to therapeutic drugs.

摘要

许多人类遗传性疾病导致蛋白质 N-糖基化缺陷,但很少有细胞标记物可用于测试此类缺陷的基因互补。质膜糖蛋白是潜在的生物标志物,因为它们在糖基化缺陷细胞的质膜中可能减少甚至不存在。我们将稳定同位素标记的氨基酸在细胞培养中的应用(SILAC)与线性离子阱质谱(LTQ Orbitrap(TM))相结合,用于鉴定和定量野生型 CHO 和糖基化缺陷型 CHO(Lec9)细胞的膜蛋白。我们从 1447 个独特定量的蛋白质中鉴定出 165 个代表性不足的蛋白质,其中包括 18 种 N-糖基化的质膜蛋白。通过各种方法,我们发现与正常对照相比,Lec9 细胞和 31 名先天性糖基化障碍(CDG)患者的成纤维细胞中细胞间黏附分子 1(ICAM-1)减少。磷酸甘露糖异构酶缺陷型 CDG-Ib(MPI-CDG)细胞的甘露糖补充和 PMM2 缺陷型 CDG-Ia(PMM2-CDG)细胞的 PMM2 互补部分纠正了低聚糖基化,这基于 ICAM-1 在质膜上的存在增加。这些数据表明,ICAM-1 可以作为一种有用的低聚糖基化生物标志物,用于评估 CDG-I 患者细胞的基因互补,并监测治疗药物引起的糖基化改善。

相似文献

引用本文的文献

7
The Metabolic Map into the Pathomechanism and Treatment of PGM1-CDG.PGM1-CDG 的代谢图谱与发病机制及治疗
Am J Hum Genet. 2019 May 2;104(5):835-846. doi: 10.1016/j.ajhg.2019.03.003. Epub 2019 Apr 11.
10
CDG Therapies: From Bench to Bedside.CDG 疗法:从基础研究到临床应用。
Int J Mol Sci. 2018 Apr 27;19(5):1304. doi: 10.3390/ijms19051304.

本文引用的文献

8
Metabolic manipulation of glycosylation disorders in humans and animal models.人类和动物模型中糖基化紊乱的代谢操纵。
Semin Cell Dev Biol. 2010 Aug;21(6):655-62. doi: 10.1016/j.semcdb.2010.03.011. Epub 2010 Apr 2.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验